Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frankfurt (oder) – page 3

61 clinical trials in Frankfurt (oder), Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frankfurt (oder) at a glance
61
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Frankfurt (oder)

Open in trial search

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.

Study of RO7269162 in people at risk for or with early-stage Alzheimer's Disease: Effects on brain amyloid buildup

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Not recruiting

Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Hodgkin's disease

Not recruiting

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Plasma cell myeloma

Not recruiting

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Gastrooesophageal cancer+1

Not recruiting

Study on Organ Preservation for Early Stage Esophageal Cancer Using Durvalumab and Chemoradiation for Patients Eligible for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frankfurt (oder)

What the registry says about research in the country

01 Hemic and Lymphatic Diseases

Clinical research in Frankfurt (oder) is strongly focused on blood cancers, with studies covering follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and multiple myeloma. These trials are mainly testing new treatment combinations and comparing them with current standard care to improve response and disease control.

  • New approaches for follicular lymphoma and related indolent lymphomas
  • Treatment studies in relapsed or refractory lymphoma and B-cell non-Hodgkin’s lymphoma
  • Therapy comparisons for chronic lymphocytic leukemia in patients with other health conditions
  • Trials in multiple myeloma and other hematologic cancers

The overall goal is to find safer and more effective options for patients with complex hematologic malignancies, especially where long-term disease control is a priority.

02 Neoplasms

Another major area of trial activity is cancer research in broader tumor types, including diffuse large B-cell lymphoma and other aggressive lymphomas. These studies are evaluating whether newer targeted or combined therapies can improve outcomes for older adults and people who may not tolerate intensive treatment well.

  • Studies for diffuse large B-cell lymphoma and other aggressive B-cell lymphomas
  • Research in older or less fit patients needing gentler treatment options
  • Comparisons of new immunotherapy-based regimens with standard chemotherapy
  • Trials designed to improve remission rates and disease-free survival

This reflects a practical effort to refine treatment choices in oncology, with attention to both effectiveness and tolerability.

03 Nervous System Diseases

Clinical trials in nervous system disease are centered on Alzheimer’s disease, exploring whether an investigational therapy can be safe and well tolerated while also influencing disease-related brain changes. The research aims to support earlier intervention and improve understanding of how treatment may affect the course of memory and cognitive decline.

  • Studies in Alzheimer’s disease at risk and early symptom stages
  • Research on safety and tolerability of a potential new therapy
  • Evaluation of effects on brain amyloid accumulation
  • Work aimed at better treatment strategies for neurodegenerative disease

These trials contribute to efforts in neurology to slow progression and improve future care for people affected by cognitive disorders.

04 Mixed Hematologic and Oncology Research

Several studies in the city also bridge multiple areas of hematology and oncology, including treatment strategies for patients preparing for allogeneic stem cell transplantation. These trials are looking at whether alternative regimens can better control disease before transplant and improve outcomes afterward.

  • Research in higher-risk MDS and oligoblastic AML
  • Treatment planning before allogeneic blood cell transplantation
  • Studies comparing disease control strategies ahead of transplant
  • Focus on improving progression-free and event-free survival

The research supports more tailored treatment pathways for patients with challenging blood disorders and advanced cancer-related conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.